Methamphetamine, amphetamine, MDMA ('ecstasy'), MDA and mCPP modulate electrical and cholinergic input in PC12 cells

NeuroToxicology

Volumn 33, Issue 2, 2012, Pages 255-260

  Hondebrink, Laura ^a,b   Meulenbelt, Jan ^a,b,c   Rietjens, Saskia J ^b   Meijer, Marieke ^a   Westerink, Remco H S ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acetylcholine receptors; Ca 2+ homeostasis; Drugs of abuse; Fura 2 calcium imaging; PC12 cells; Voltage gated calcium channels

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCHOLINE; AMPHETAMINE; CALCIUM ION; DOPAMINE; FURA 2; METHAMPHETAMINE; NICOTINIC RECEPTOR; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL MEMBRANE DEPOLARIZATION; CELL STIMULATION; CHOLINERGIC SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ABUSE; IN VITRO STUDY; MOLECULAR IMAGING; NERVE CELL MEMBRANE POTENTIAL; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-METHYLENEDIOXYAMPHETAMINE; ADRENERGIC AGENTS; AMPHETAMINE; ANIMALS; CALCIUM; CHOLINERGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MEMBRANE POTENTIALS; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PC12 CELLS; PIPERAZINES; POTASSIUM CHLORIDE; RATS; SEROTONIN RECEPTOR AGONISTS;

EID: 84858007241     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.09.003     Document Type: Article

References (31)

1. Angrist B., Corwin J., Bartlik B., Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry 1987, 722:1357-1368.
2. Bossong M.G., Brunt T.M., Van Dijk J.P., Rigter S.M., Hoek J., Goldschmidt H.M., et al. mCPP: an undesired addition to the ecstasy market. J Psychopharmacol 2010, 24:1395-1401.
3. Cachelin A.B., Jaggi R. Beta subunits determine the time course of desensitization in rat alpha 3 neuronal nicotinic acetylcholine receptors. Pflugers Arch 1991, 419:579-582.
4. Camarasa J., Marimon J.M., Rodrigo T., Escubedo E., Pubill D. Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats. Eur J Pharmacol 2008, 589:132-139.
5. Capela J.P., Carmo H., Remiao F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009, 39:210-271.
6. Chipana C., Torres I., Camarasa J., Pubill D., Escubedo E. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 2008, 754:1254-1263.
7. Chu T., Kumagai Y., DiStefano E.W., Cho A.K. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 1996, 51:789-796.
8. Collins A.C., Salminen O., Marks M.J., Whiteaker P., Grady S.R. The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb Exp Pharmacol 2009, 85-112.
9. Cook C.E., Jeffcoat A.R., Sadler B.M., Hill J.M., Voyksner R.D., Pugh D.E., et al. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 1992, 20:856-862.
10. de la Torre R., Farre M., Ortuno J., Mas M., Brenneisen R., Roset P.N., et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 2000, 49:104-109.
11. 2+ und pH, Ionenmessungen in Zellen und Geweben 2000, 77-97. Spektrum Akademischer Verleger, Heidelberg. F. Wigger, M. Mechler (Eds.).
12. Drew A.E., Derbez A.E., Werling L.L. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 2000, 38:10-16.
13. Engelman H.S., MacDermott A.B. Presynaptic ionotropic receptors and control of transmitter release. Nat Rev Neurosci 2004, 5:135-145.
14. Garcia-Rates S., Camarasa J., Sanchez-Garcia A.I., Gandia L., Escubedo E., Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. Toxicol Appl Pharmacol 2010, 244:344-353.
15. Gijsman H.J., Van Gerven J.M., Tieleman M.C., Schoemaker R.C., Pieters M.S., Ferrari M.D., et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chloro-phenylpiperazine in healthy volunteers. J Clin Psychopharmacol 1998, 18:289-295.
16. Greene L.A., Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976, 73:2424-2428.
17. Hondebrink L., Meulenbelt J., Timmerman J.G., van den Berg M., Westerink R.H. Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following l-DOPA exposure. J Neurochem 2009, 111:624-633.
18. Hondebrink L., Meulenbelt J., Meijer M., van den Berg M., Westerink R.H. High concentrations of MDMA ('ecstasy') and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells. Neuropharmacology 2011, 61:202-208.
19. Kovaleva J., Devuyst E., De Paepe P., Verstraete A. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 2008, 30:394-398.
20. Lester D.B., Rogers T.D., Blaha C.D. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010, 16:137-162.
21. 2+ entry and catecholamine release via nicotinic receptor activation in bovine adrenal chromaffin cells. Eur J Pharmacol 2003, 460:9-17.
22. Lopez M.G., Fonteriz R.I., Gandia L., de la Fuente M., Villarroya M., Garcia-Sancho J., et al. The nicotinic acetylcholine receptor of the bovine chromaffin cell, a new target for dihydropyridines. Eur J Pharmacol 1993, 247:199-207.
23. MacDermott A.B., Role L.W., Siegelbaum S.A. Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 1999, 22:443-485.
24. Mueller M., Yuan J., Felim A., Neudorffer A., Peters F.T., Maurer H.H., et al. Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 2009, 37:2079-2086.
25. Nacca A., Guiso G., Fracasso C., Cervo L., Caccia S. Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents. Br J Pharmacol 1998, 125:1617-1623.
26. Romanelli M.N., Gratteri P., Guandalin L., Martini E., Bonaccini C., Gualtieri F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem 2007, 2:746-767.
27. Shafer T.J., Atchison W.D. Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies. Neurotoxicology 1991, 12:473-492.
28. Spitzmaul G.F., Esandi M.C., Bouzat C. Amphetamine acts as a channel blocker of the acetylcholine receptor. Neuroreport 1999, 10:2175-2181.
29. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 5:406-433.
30. Westerink R.H. Targeting exocytosis: ins and outs of the modulation of quantal dopamine release. CNS Neurol Disord Drug Targets 2006, 5:57-77.
31. Westerink R.H., Ewing A.G. The PC12 cell as model for neurosecretion. Acta Physiol (Oxf) 2008, 192:273-285.